Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Novartis, Abbott Earnings; Using mL Cuts Mis-Dosing; Labels Need Proprietary Blend, Capsule Ingredients

This article was originally published in The Tan Sheet

Executive Summary

Novartis consumer up 5%; adult products drive Abbott Nutrition growth; medication errors drop when mL is unit of measurement; ingredients of proprietary blends must be labeled; include capsule ingredients on labels; and Herbalife defends nutrition clubs.

You may also be interested in...

CHPA Adopts Dosing Guidelines For OTC Pediatric Liquids

The Consumer Healthcare Products Association recommends a standardized labeling format for OTC pediatric oral liquids to help prevent accidental overdoses and misdosing

FDA Gets Strict On Liquid OTC Dosing Devices In Draft Guidance

Some drug firms may need to alter their product packaging and labeling to comply with FDA's guidance on dosing device labeling for liquid OTCs

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts